

# Optimize reimbursement claims for ZUSDURI™ using HCPCS code J9282



Always bill for 80 mg ZUSDURI regardless of the amount instilled into the patient.



Illustrative only. For more information, see Instructions for Pharmacy and Instructions for Administration.

**80 mg ZUSDURI is supplied in each kit**

ZUSDURI is supplied in a Single-Dose Kit containing **two 40-mg vials of mitomycin and a single vial of hydrogel that need to be mixed**



**80 mg ZUSDURI in reconstituted vial prepared by pharmacy**

After the two 40-mg mitomycin vials and the hydrogel are reconstituted by an in-house pharmacy or mixing partner, **a single vial with 80 mg ZUSDURI is available for administration**



**ZUSDURI instillation amount is 75 mg**

The recommended dose of ZUSDURI is 75 mg

**5 mg ZUSDURI discarded from 80-mg vial**

## Use the correct HCPCS code and modifier to ensure accurate reimbursement

The following **permanent J-Code for ZUSDURI** is approved for all sites of care on January 1, 2026:

**J9282**

ZUSDURI (mitomycin) for intravesical instillation, 1 mg

### Sample CMS-1500 claim form

#### Box 24G: Days or service units

When billing with **HCPCS code J9282**, bill for units instilled. For the remaining mg not instilled, bill with HCPCS code J9282 and the JW modifier. Click [here](#) for detailed information in the ZUSDURI Annotated Claim Form. The image shown is not a complete depiction of the CMS-1500 form; portions of the full form are not shown.

## The total billable units under J9282 are 80 mg.

J9282 has a unit description of 1 mg. The recommended dose of ZUSDURI is 75 mg (56 mL). Report a total of 80 mg billing units divided between 2 lines, based on the appropriate number of units (1 billing unit = 1 mg) instilled to the patient and number of units discarded.

24	A	DATE(S) OF SERVICE	B	C	D	E	F	G	H
MM	DD	YY	MM	DD	YY	11	J9282	A	XXXX
1		N472493010603ME75							
		MM DD YY MM DD YY	11						75
2		N472493010603ME5							
		MM DD YY MM DD YY	11			J9282	JW		5

On the first line, enter the appropriate number of ZUSDURI units (1 billing unit = 1 mg) instilled to the patient using J9282.

The amount will always be 75 mg.

On the second line, use the JW modifier to account for wastage, to bill the number of units discarded (1 billing unit = 1 mg). Make sure to document the amount of discarded drug in the patient's medical record.

The amount of waste will always be 5 mg.

**80 mg ZUSDURI in purchased Single-Dose Kit**



**75 mg ZUSDURI administered to patient**  
**5 mg ZUSDURI discarded**

**J9282 billed amount = 75 mg**

**JW modifier = 5 mg**

**Total billable amount is 80 mg**

Content is informational only and does not constitute medical, legal, or reimbursement advice and represents no statement, promise, or guarantee of payment. The provider is solely responsible for determining appropriate treatment for the patient based on the unique medical needs of each patient and the independent judgment of the provider. It is also the responsibility of the provider to determine payer appropriate coding, medical necessity, site of service, documentation requirements and payment levels, and to submit appropriate codes, modifiers, and charges for services rendered. Although we have made every effort to provide information that is current at the time of its issue, it is recommended you consult your legal counsel, reimbursement/compliance advisor, and/or payer organization(s) for interpretation of payer specific coding, coverage, and payment expectations.

**Please see Important Safety Information on page 2 and [click here](#) for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.**



## INDICATIONS AND USAGE

ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

## IMPORTANT SAFETY INFORMATION

### Contraindications

ZUSDURI is contraindicated in patients with perforation of the bladder or in patients with prior hypersensitivity reactions to mitomycin or any component of the product.

### Warnings and Precautions

#### Risks in Patients with Perforated Bladder

ZUSDURI may lead to systemic exposure to mitomycin and severe adverse reactions if administered to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised. Evaluate the bladder before the intravesical instillation of ZUSDURI and do not administer to patients with a perforated bladder or mucosal compromise until bladder integrity has been restored.

#### Embryo-Fetal Toxicity

Based on findings in animals and mechanism of action, ZUSDURI can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of mitomycin resulted in teratogenicity. Advise females of reproductive potential to use effective contraception during treatment with ZUSDURI and for 6 months following the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZUSDURI and for 3 months following the last dose.

### Adverse Reactions

#### Common Adverse Reactions

The most common ( $\geq 10\%$ ) adverse reactions, including laboratory abnormalities, that occurred in patients treated with ZUSDURI were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

### Additional Adverse Reactions Information

Clinically relevant adverse reactions occurring in  $<10\%$  of patients who received ZUSDURI included increased urinary frequency, fatigue, urinary incontinence, urinary retention, urethral stenosis, genital pain, urinary urgency, genital edema, genital pruritus, genital rash, urethritis, acute kidney injury, balanoposthitis, and nocturia.

### Use in Specific Populations

#### Lactation

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ZUSDURI and for 1 week following the last dose.

### Preparation and Administration Information

**ZUSDURI is to be administered by intravesical instillation only.** Do not administer ZUSDURI by pyelocalyceal instillation or by any other route.

ZUSDURI must be prepared and administered by a healthcare provider. To ensure proper dosing, it is important to follow the preparation instructions found in the ZUSDURI Instructions for Pharmacy and administration instructions found in the ZUSDURI Instructions for Administration.

ZUSDURI may discolor urine to a violet to blue color following the instillation procedure. Advise patients for at least 24 hours post-instillation to avoid urine contact with skin, to void urine sitting on a toilet, and to flush the toilet several times after use. Advise patients to wash hands, perineum or glans with soap and water after each instillation procedure.

ZUSDURI is a hazardous drug. Follow applicable special handling and disposal procedures.

**Please click here for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.**



### Reimbursement and Patient Support

To learn more about ZUSDURI, please visit [UROGENSUPPORT.com](https://UROGENSUPPORT.com) or call 833-UROGEN1 (833-876-4361).

CMS, Centers for Medicare & Medicaid Services; HCPCS, Healthcare Common Procedure Coding System.

**Reference:** Centers for Medicare & Medicaid Services. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Determinations. Third Quarter, 2025 HCPCS Coding Cycle. U.S. Department of Health & Human Services; 2025. Accessed November 4, 2025. <https://www.cms.gov/files/document/2025-hcpcs-application-summary-quarter-3-2025-drugs-biologicals.pdf>



UroGen® is a registered trademark and ZUSDURI™ and UroGen Support™ are trademarks of UroGen Pharma, Ltd. All other trademarks are the property of their respective owners. © 2026 UroGen Pharma, Inc. All rights reserved. US-ZUS-00204 01/26